Skip to main content
Caplight Logo









CureAge Therapeutics

CureAge Therapeutics

Private
LondonHealthcare & Life Scienceshttps://www.cureagetx.com/

Last Round

Grant

Jul 16, 2026

Total Funding Raised

$670,000

Momentum

Top 5%

of companies Caplight tracks

Company Overview

CureAge Therapeutics is a biotechnology company that develops genetic therapies using lipid nanoparticle delivery systems to treat neurofibromatosis type 1 and other peripheral nerve disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B

Customer Profile

Government Contracts, Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologydrug discoverysmall molecule therapeuticscellular senescenceage-related diseaseslongevity biotechlipid nanoparticleLNPgenetic medicinepreclinical researchdrug development pipelineneurofibromatosis type 1NF1anti-aging drugsbiotech R&D

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

CureAge Therapeutics Comparables

Compare CureAge Therapeutics with similar companies based on industry and business-model similarity.

CureAge Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Rubedo Life Sciences
84%
Turn Biotechnologies
79%
Retro Biosciences
76%

CureAge Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantJul 16, 2026
Pre SeedJan 1, 2025

Key People

Founding team and executive leadership

Liron Elkouby

Co-Founder and CTO

Founding Team

Gonzalo Fernández-Miranda

Co-Founder and CEO

Founding Team

CureAge Therapeutics Investors

Notable investors and investment history

CureAge Therapeutics investors
InvestorRounds
Deep Science VenturesGrant, Pre Seed
Innovate UKGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 1, 2026

    Grew 100% QoQ from 3 to 6 employees.

  • Jul 16, 2026

    $670K raised from Deep Science Ventures and others.

CureAge Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

CureAge Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about CureAge Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersLondon
Employee Range6
Year Founded2024
Last FundingJul 16, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?